Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

IXODES GmbH intends to develop SHB001, an azithromycin dermal formulation in order to prevent Lyme disease at early stages of infection after tick bite.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Zurich
• Collaborators: Appletree AG; Ixodes GmbH

Criteria

Main inclusion criteria:

• Male or female healthy volunteers, age 18 - 70 years

Main exclusion criteria:

• A known hypersensitivity against azithromycin, erythromycin or any of the macrolide antibiotics

• A known hypersensitivity against lidocaine

• Treatment by any route with any macrolide antibiotic within the last 2 month